HER2-positive feline mammary carcinoma

被引：5
|
作者：
Marques, Claudia [1 ]
Correia, Jorge [1 ]
Ferreira, Fernando [1 ]
机构：
[1] Univ Lisbon, Fac Vet Med, Ctr Interdisciplinary Res Anim Hlth, P-1300477 Lisbon, Portugal
来源：
AGING-US | 2016年 / 8卷 / 08期
关键词：
feline mammary carcinoma; HER2-positive subtype; sHER2; cancer model;
D O I：
10.18632/aging.101015
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：1574 / 1575
页数：2
相关论文
共 50 条
  • [41] Correlation of Src Activation with Trastuzumab Response in Patients with HER2-Positive Breast Carcinoma
    Gallardo, A.
    Lerma, E.
    Ortiz-Martinez, F.
    Perez-Balaguer, A.
    Adrover, E.
    Tibau, A.
    Barnadas, A.
    Aranda, F.
    Peiro, G.
    MODERN PATHOLOGY, 2013, 26 : 41A - 41A
  • [42] HER2-Positive Metaplastic Spindle Cell Carcinoma Associated with Synchronous Bilateral Apocrine Carcinoma of the Breast
    Kito, Katsumi
    Maeda, Toshiharu
    Ninomiya, Keiko
    Sugita, Atsuro
    Sagawa, Teiri
    Matsuoka, Kinya
    Kinoshita, Kousei
    Hyodo, Naoki
    Morita, Nagisa
    Furuya, Keizo
    CASE REPORTS IN PATHOLOGY, 2014, 2014
  • [43] Correlation of Src Activation with Trastuzumab Response in Patients with HER2-Positive Breast Carcinoma
    Gallardo, A.
    Lerma, E.
    Ortiz-Martinez, F.
    Perez-Balaguer, A.
    Adrover, E.
    Tibau, A.
    Barnadas, A.
    Aranda, F.
    Peiro, G.
    LABORATORY INVESTIGATION, 2013, 93 : 41A - 41A
  • [44] HER2-positive pure mucinous breast carcinoma A case report and literature review
    Zhao, Xingjuan
    Yang, Xuan
    Gao, Runfang
    Zhai, Liqin
    Yang, Lizhu
    Yu, Keda
    MEDICINE, 2020, 99 (33) : E20996
  • [45] Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
    Peiro, G.
    Ortiz-Martinez, F.
    Gallardo, A.
    Perez-Balaguer, A.
    Sanchez-Paya, J.
    Ponce, J. J.
    Tibau, A.
    Lopez-Vilaro, L.
    Escuin, D.
    Adrover, E.
    Barnadas, A.
    Lerma, E.
    BRITISH JOURNAL OF CANCER, 2014, 111 (04) : 689 - 695
  • [46] Successful treatment with trastuzumab in HER2-positive squamous cell carcinoma of the head and neck
    Saleh, Khalil
    Saada, Esma
    Auger, Nathalie
    Mayache-Badis, Lamia
    Casiraghi, Odile
    Bidault, Francois
    Bahleda, Rastislav
    Even, Caroline
    ORAL ONCOLOGY, 2019, 91 : 129 - 131
  • [47] Significance of Src Activation Status in Trastuzumab Response in HER2-Positive Breast Carcinoma
    Gallardo, A.
    Lerma, E.
    Ortiz-Martinez, F.
    Adrover, E.
    Tibau, A.
    Barnadas, A.
    Giner, D.
    Aranda, F. I.
    Gutierrez-Avino, F. J.
    Peiro, G.
    LABORATORY INVESTIGATION, 2012, 92 : 40A - 40A
  • [48] Axillary Lymph Node Status and neoadjuvant Therapy in HER2-positive Breast Carcinoma
    Danzinger, S.
    Pfeifer, C.
    Wimmer, S.
    Tendl-Schulz, K.
    Singer, C. F.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (04) : 3 - 3
  • [49] Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma
    Shih, Chia-Hsien
    Lin, Yu-Hua
    Luo, Hao-Lun
    Sung, Wen-Wei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [50] HER2Δ16 expression in HER2-positive breast cancer
    De Yao, Jocelyn Torres
    Sun, Danyu
    Galehouse, Donna
    Shorten, Scott
    Haller, Nairmeen
    Rehmus, Esther Hoogland
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345